Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Oatly Group AB - ADR — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.5 (market cap $8.04B), while Oatly Group AB - ADR trades at $9.98 (market cap $304.76M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 26.4× Oatly Group AB - ADR's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| BIO | OTLY | |
|---|---|---|
Market Cap | $8.04B | $304.76M |
Sector | Health | Consumer Staples |
52-Week High | $339.75 | $18.54 |
52-Week Low | $241.71 | $8.03 |
Enterprise Value | $7.85B | $802.37M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Oatly (OTLY) trades at $10.00, up 1.52% today, showing modest momentum despite ongoing financial challenges. The company maintains a low P/S ratio of 0.35 but suffers from negative profitability metrics including a -17.06% net income margin and -245.57% ROE. Recent Q1 2026 earnings beat expectations with a smaller loss than projected, while technical indicators show mixed signals with an overall bullish bias. Cash flow remains negative but has improved from previous years, with operating cash burn narrowing to -$24 million in 2025.
Oatly faces significant execution risks with persistent losses and high debt levels (66.53% debt-to-asset ratio), though revenue growth continues and cash burn shows improvement. Analyst sentiment is divided with 44% buy ratings but 50% hold recommendations, reflecting cautious optimism about the company's turnaround potential amid competitive pressures in the plant-based beverage market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
